Sharon Mates - 22 Jan 2026 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Reporting relationship
Director
Issuer ticker
BNTC
Reported as of
22 Jan 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Jan 2026, 16:10:15 UTC
Prior SEC filing
03 Dec 2025
Next SEC filing
30 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Sharon Mates

Key filing fact

Sharon Mates filed Form 4 for Benitec Biopharma Inc. (BNTC) on 26 Jan 2026.

Key facts

  • This page summarizes Sharon Mates's Form 4 filing for Benitec Biopharma Inc. (BNTC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 26 Jan 2026, 16:10.

Change

  • Previous filing in this sequence was filed on 03 Dec 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001585699 Primary reporting owner

Mates Sharon

Relationship
Director
Address
C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD
Signature
/s/ Sharon Mates
Signature date
26 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNTC transaction Derivative

Options (right to buy)

Award

Transaction value
$0
Shares
+31,500
Change %
Price
$0.000000
Shares after
31,500
Date
22 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,500
Exercise price
$12.83
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .